Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV004555178 | SCV005044107 | likely pathogenic | Velocardiofacial syndrome; DiGeorge syndrome | 2022-02-11 | criteria provided, single submitter | clinical testing | The inherited c.35-1G>A [NM_080647.1] splice-site variant identified has not been reported in affected individuals in the literature. The variant has 0.000006839 allele frequency in the gnomAD(v3) database [1 out of 146230 heterozygous alleles, no homozygote] suggesting it is not a common benign variant in populations represented in that database. The c.35-1G>A splice-site variant affects the canonical splice acceptor site in intron 2 (of 8) and is predicted to cause skipping of exon 3 of TBX1 gene. Exon 3 skipping is predicted to disrupt the wildtype translational reading frame and subject the transcript to nonsense-mediated mRNA decay. Loss-of-function variants in the TBX1 gene have been reported in affected individuals in the literature [PMID: 25860641, 29500247]. Depending on the mutation type and its localization, loss-of-function as well as dominant negative/gain-of-function effects have been proposed which may explain the extreme phenotypic variability among affected individuals [PMID: 25860641, 29500247, 17273972]. Based on the available evidence, the inherited c.35-1G>A splice-site variant identified is reported as Likely Pathogenic. |